AMR Centre teams up to tackle gonorrhoea

  20 March 2020

The project is targeting multi-drug resistant gonorrhoea and will see AMRC undertake pre-clinical development to drive Microbiotix’s novel mechanism drug, a Trans T ribosome rescue inhibitor, through lead optimisation and into pre-clinical nomination.

The collaboration is currently receiving $2.86 million in grant funding and could receive an additional $16 million if certain development milestones are met. The funding is being offered by CARB-X, an organisation which helps accelerate global antibacterial projects.

Author(s): European Pharmaceutical Manufacturer
Healthy Patients   Smart Innovations  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!